Suspension of trading
Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
| Market Cap | 819.15Cr 718.47Cr 663.31Cr 612.96Cr 1.16TCr 78TCr 1.19TCr 7.97TCr 3.1TCr 38TCr 3.08TCr 3.01TCr 1,33200Cr | P/E 2022 |
-13.6x | P/E 2023 | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 749.61Cr 657.48Cr 607Cr 560.92Cr 1.06TCr 72TCr 1.08TCr 7.3TCr 2.84TCr 35TCr 2.82TCr 2.75TCr 1,21900Cr | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
93.64% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +0.74% |
| 3 years | 19.59 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Reents
PSD | President | 59 | 01/08/2024 |
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
Scott Reents
BRD | Director/Board Member | 59 | 01/08/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01/24/01 | Issuer sale | General Counsel | 4,33,824 | 0.2381% | ||
| 01/24/01 | Issuer sale | Chief Financial Officer | 2,22,146 | 0.1219% | ||
| 01/24/01 | Issuer sale | Director | 1,54,118 | 0.0846% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | -.--% | +49.07% | 819.15Cr | |
| -1.53% | +0.78% | +72.33% | +129.70% | 5.67TCr | |
| -2.45% | -7.83% | +63.92% | +83.15% | 5.13TCr | |
| +3.27% | +8.91% | +21.21% | +486.76% | 2.53TCr | |
| -0.81% | -0.42% | -16.24% | -12.47% | 2.37TCr | |
| +4.71% | +3.90% | +43.86% | -1.95% | 1.87TCr | |
| -0.24% | +5.11% | +38.76% | -26.41% | 1.77TCr | |
| +2.34% | +12.50% | +224.02% | +380.99% | 1.77TCr | |
| -0.58% | +1.80% | +36.08% | - | 1.43TCr | |
| -1.70% | +3.98% | +28.96% | +190.57% | 1.41TCr | |
| Average | +0.34% | +3.61% | +51.29% | +142.16% | 2.48TCr | |
| Weighted average by Cap. | -0.23% | +2.13% | +56.25% | +141.22% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -35Cr -31Cr -28Cr -26Cr -50Cr -3.37TCr -51Cr -342.18Cr -132.96Cr -1.65TCr -132Cr -129.11Cr -5.72TCr | -43Cr -38Cr -35Cr -32Cr -61Cr -4.14TCr -63Cr -421.36Cr -163.72Cr -2.03TCr -162.55Cr -158.98Cr -7.04TCr |
| Net Debt | -52Cr -46Cr -42Cr -39Cr -74Cr -5.01TCr -76Cr -509.35Cr -197.91Cr -2.45TCr -196.49Cr -192.18Cr -8.51TCr | -70Cr -61Cr -56Cr -52Cr -99Cr -6.66TCr -100.6Cr -676.93Cr -263.02Cr -3.26TCr -261.14Cr -255.42Cr -11TCr |
Employees
355
- Stock Market
- Stocks
- CERE Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
